US3217001A - Derivatives of 1h-2, 1, 3-benzothiadiazin-4(3h)-one 2-oxide and intermediates therefor - Google Patents

Derivatives of 1h-2, 1, 3-benzothiadiazin-4(3h)-one 2-oxide and intermediates therefor Download PDF

Info

Publication number
US3217001A
US3217001A US303155A US30315563A US3217001A US 3217001 A US3217001 A US 3217001A US 303155 A US303155 A US 303155A US 30315563 A US30315563 A US 30315563A US 3217001 A US3217001 A US 3217001A
Authority
US
United States
Prior art keywords
alkyl
chloro
benzothiadiazin
oxide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US303155A
Inventor
Arthur A Santilli
Thomas S Osdene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Priority to US303155A priority Critical patent/US3217001A/en
Application granted granted Critical
Publication of US3217001A publication Critical patent/US3217001A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines

Definitions

  • the compounds of this invention may be characterized as having a 11-1 2,1,3 benzothiadiazin 4(3I-I) one 2-oxide nucleus to which is attached: in the 1-position, a lower alkyl group; in the 3-position, a lower alkyl, an halo(1ower)alkyl, an alkoxyalkyl, a phenyl(lower)alkyl, an halophenyl(lower)alkyl, or a cycloalkyl group and optionally, in the 6-position, a hydrogen atom, a halogen atom, a nitro group, or a lower alkylsulfamoyl group.
  • R' is lower alkyl preferably having from 1 to 4 carbon atoms in the alkyl chain, halo(lower)alky1 preferably having from 1 to 4 carbon atoms, lower alkoxy (lower) alkyl preferably having from 1 to 4 carbon atoms, phenyl(lower)alkyl preferably having from 1 to 4 carbon atoms in the alkyl chain, halo phenyl(lower)alkyl preferably having from 1 to 4 carbon atoms in the alkyl chain, or a cycloalkyl group preferably having up to 6 carbon atoms;
  • X is hydrogen, chlorine, nitro, or a lower alkylsulfamoyl group preferably having up to 2 carbon atoms in the alkyl chain;
  • R is lower alkyl preferably having from 1 to 4 carbon atoms.
  • the term alkyl refers both to the normal and the branched chain radicals.
  • the intermediates which occur in the synthesis of the present compounds may be characterized as having a 2-(lower)alkyl-aminobenzamide nucleus having attached thereto, in the -position, a hydrogen atom, a halogen atom, a nitro group or a lower alkylsulfamoyl group; on the nitrogen atom of the amido group, a lower alkyl group, a halo(lower)alkyl, an alkoxyalkyl, a hydroxyalkyl, a phenyl(lower)alkyl, an halo phenyl(lower) alkyl group or a cycloalkyl group.
  • These intermediates are represented by the structural formula:
  • the compounds of this invention are prepared by amidating in an equeous or alcoholic solvent'or in a mix- 3,217,001 Patented Nov. 9, 1965 ture of such solvents a N-(lower) alkyl isatoic anhydride (III) of the formula:
  • Example 1 To a solution of 3.1 g. of ethanolamine in 40 ml. of ethanol was added 10.5 g. of 6-ch'loro-N-methylisatoic 'anhydride. The reaction mixture was warmed for a few minutes on the steam bath. After the evolution of carbon dioxide was complete, the solvent was removed on a rotary evaporator. The oily residue crystallized to a solid mass on cooling and amounted to 6.7 g., M.P. 1-l6122. Recrystallization from benzene afforded 5-chloro-N-(2-hydroxyethyl)-2-methylaminobenzamide, M.P. 125 .5129.
  • this compound When tested pharmacologically, this compound exhibited analgesic, diuretic, anticonvulsant, and anti-tremorine activities.
  • Example 2 To 50 ml. of 33% aqueous ethylamine solution was added 5.2 g. of 6-chloro-N-methylisatoic anhydride. After warming for a few minutes on the steam bath, the evolution of carbon dioxide ceased. The reaction mixture was allowed to stand an additional hour at room temperature. The crystalline material which deposited out of solution amounted to 5.2 g., M.P. 109112. Recrystallization from cyclohexane gave S-chloro-N-ethyl-Z- methylaminobenz amide, M.P. 96.5.'
  • this compound When tested pharmacologically, this compound exhibited analgesic, anti-metrazol and anti-tremorine activities.
  • Example 3 To a solution of 7.1 g. of o-chlorobenzylamine in 50 ml. of ethanol was added 11.5 g. of 6-chloro-N-methylisatoic anhydride. The reaction mixture was heated on the steam bath until the evolution of carbon dioxide ceased, and complete dissolution of solids was attained. The reaction mixture was filtered. A white crystalline product was deposited out of solution which amounted to 9.9 g., M.P. 133-6. Recrystallization of the product from ethanol afforded 5-chloro-N-(o-chlorobenzyl)-2- methylaminobenzamide, M.P. 137.5-139.
  • Example 4 To a solution of 4.5 g. of 2-ethoxyethylamine in 50 ml. of ethanol was added 11.5 g. of 6-chloro-N-methylisatoic anhydride. After the evolution of carbon dioxide had abated, the reaction mixture was heated for an additional 5 minutes on the steam bath. The solvent was removed on a rotary evaporator. The residual oil crystallized on standing in the cold room. The product, which amounted to 13.0 g., M.P. 50-63", was recrystallized from cyclohexane affording 5-chloro-N-(2-ethoxyethyl)-2-methylaminobenzamide, M.P. 73.4.
  • this compound When tested pharmacologically, this compound exhibited analgesic, anticonvulsant and central nervous system depressant activities.
  • Example 5 T o a solution of 9.68 g. of phenethylamine in 50 ml. of ethanol was added 15.9 g. of 6-chloro-N-methylisatoic anhydride. A brisk evolution of carbon dioxide occurred after warming for a few minutes on the steam bath. When gas evolution had abated, the reaction mixture was heated to the boiling point until dissolution of the solids had occurred. The reaction mixture was filtered. A white crystalline product was deposited out of solution. This on removal amounted to 16.0 g., M.P. 126-131. The product was recrystallized from ethanol afiording 5- chloro 2 methylamino N phenethylbenzamide, M.P. 132-4".
  • Example 6 To a solution of 6.4 g. of cyclopentylamine in 40 m1. of ethanol was added 15.9 g. of 6-chloro-N-methylisatoic anhydride. The reaction mixture was heated for a few minutes on the steam bath until the evolution of carbon dioxide was completed. The solvent was removed on the rotary evaporator. The solid residue amounted to 16.5 g., M.P. 59-85. Recrystallization of the product from cyclohexane afforded 5-chloro-N-cyclopentyl-2-methylaminobenzamide, M.P. 153-5.
  • Example 7 To a solution of 3.1 g. of 2-hydroxyethylamine in 40 ml. of ethanol was added 11.1 g. of 6-nitro-N-methylisatoic anhydride. After the evolution of carbon dioxide was complete, the reaction mixture was heated on the steam bath for a few minutes. The yellow crystalline product which separated was removed by filtration. The product weighed 9 g., M.P. 160-5". Recrystallization from ethyl acetate afforded N-(Z-hydroxyethyl)-2-methylamino-S-nitrobenzamide, M.P. 173-4.
  • this compound When tested pharmacologically, this compound exhibited analgesic, anticonvulsant and central nervous system depressant activities.
  • Example 9 A solution of 3.4 g. of 5-chloro-N-ethyl-2-methy1aminobenzamide in 40 ml. of thionyl chloride was boiled under reflux for 1 hour. The excess thionyl chloride was removed in vacuo on a rotary evaporator. The oil residue crystallized on cooling to give 3.9 g. of product, M.P. 89-92. The product was recrystallized from ethanol giving 6-chloro-3-ethyl-l-methyl-lH-Z,1,3-benzothiadiazin- 4(3H)-one 2-oxide, M.P. -96.5.
  • this compound When tested pharmacologically, this compound exhibited analgesic, anti-convulsant, anti-tremorine and central nervous system depressant activities.
  • Example 11 A solution of 9.3 g. of S-chloro-N-(o-chlorobenzyl)-2- methylaminobenzamide in 45 ml. of thionyl chloride was heated under reflux for 2 hours. The excess thionyl chloride was removed in vacuo on a rotary evaporator. The solid residue amounted to 10.8 g., M.P. 142-5 Recrystallization from ethanol aiforded 6-chloro-3-(o-chlorobenzyl) l-methyl-1H-2,l,3-benzothiadiazin-4(3H)-one 2-oxide,,M.P. 148-1495".
  • Example 12 A solution of 5.3 g. of S-chloro-N-(2-ethoxyethyl)-2- methylaminobenzamide in 25 ml. of thionyl chloride was boiled under reflux for 1 hour. The excess thionyl chloride was removed in vacuo on a rotary evaporator. The oily residue crystallized to a gummy solid weighing 6.2 g. Recrystallization of the product from cyclohexane afforded 6 chloro-3-(Z-ethoxyethyl)-1-methy1-1H-2,1,3-benzothiadiazin-(4(3H)-one-2-oxide, M.P. 73-4".
  • Example 13 A solution of 11 g. of 5-chloro-2-methylamino-N- phenethylbenzarnide in 40 ml. of thionyl chloride was boiled under reflux for 1 hour. The excess thionyl chloride was removed in vacuo on the rotary evaporator. The solid residue amounted to 13.0 g., M.P. 118123. The compound was recrystallized from ethanol alfording 6- chloro l methyl-3-phenethyl-1H-2,1,3-benzothiadiazin- 4(3H)-one 2-oxide, M.P. 127128.5.
  • Example 14 A solution of 5.2 g. of 5-chloro-N-cyclopentyl-2-methylaminobenzamide in 30 ml. of thionyl chloride was boiled under reflux for 2 hours. The excess thionyl chloride was removed in vacuo on a rotary evaporator. The oily residue crystallized on cooling to a solid, weighing 5 g. Recrystallization from cyclohexane afforded 6 chloro-3-cyclopentyl-1-methyl-1H2,1,3 benzothiadiazin- 4(3H)-one-2-oxide, M.P. 1279.
  • Example 16 The reaction between 8.7 g. of N-(o-chlorobenzyl)-2- methylaminobenzamide and 40 ml. of thionyl chloride as in Example 9 affords 3-(o-chlorobenzyl)-1-methyl-1H 2,1,3-benzothiadiazin-4(3H)one-2-oxide.
  • Example 17 The reaction between 50 ml. of 33% aqueous ethylamine solution and 5.65 g. of 6-chloro-N-ethylisatoic anhydride aflords 5-chloro-N-ethyl-2-ethylaminobenzamide.
  • Example 18 The reaction between 4.5 g. of S-chloro-N-ethyl-Z-ethylaminobenzamide with 40 ml. of thionyl chloride as in Example 9 affords 6-chloro-1,3-diethyl-1H-2,1,3-benzothiadiazin-4(3H)-one-2-oxide.
  • Example 19 A solution of 26.5 g. of N-methylisatoic anhydride in 70 ml. of chlorosulfonic acid was heated for 1 hour on the steam bath, cooled and poured onto ice. The solid which separated was removed by filtration and was washed several times with water. The solid was added to 75 ml. of 33% aqueous ethylamine and then heated on the steam bath for 15 minutes. After cooling the reaction mixture, there was obtained 29.5 g. of product, M.P. -105 Recrystallization from aqueous ethanol afforded N-ethyl- S-ethylsulfamoyl 2 methylaminobeuzamide, M.P. 118- 120.
  • the compounds of this invention can be administered with pharmaceutically acceptable inert carriers in a wide. variety of oral or parenteral unit dosage forms containing from 5 to 500 mg. of active ingredients for the symptomatic adjustment of the dosage to the individual patient, or in admixture with other active compounds.
  • the present invention also includes the process of bringing the compounds thereof into a form suitable for therapeutic administration by associating them with liquid or solid, pharmaceutically acceptable carriers.
  • a lower alkyl group in the 1-position: a lower alkyl group; in the 3-position: a member of the group consisting of lower alkyl, halo (lower)a1kyl, (lower)a1koxy (lower) alkyl, phenyl and halophenyl(lower)alkyl and cycloalkyl having up to six carbon atoms in the ring;
  • X is selected from the group consisting of hydrogen, halogen lower alkylsulfamoyl and nitro and R is a lower alkyl group; with a primary amine of the formula:
  • R NH wherein R is selected from the group consisting from (lower)alkyl, halo(lower) alkyl, hydroxyalkyl alkoxyalkyl, (lower)alkoxy, aralkyl, halo aralkyl and cycloalkyl to form a Z-aIkyIamino-beuzamide of the formula:
  • R is selected alkyl, alkoxyalkyl, aralkyl, halo aralkyl and cycloalkyl.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

United States Patent 3,217,001 DERIVATIVES 0F 1H 2,1,3 BENZOTHIADIAZIN- 4(3H) ONE 2 OXIDE AND INTERMEDIATES THEREFOR Arthur A. Santilli, Ardmore, and Thomas S. ()sdene, Berwyn, Pa., assiguors to American Home Products Corporation, New York, N.Y., a corporation of Delaware No Drawing. Filed Aug. 19, 1963, Ser. No. 303,155 10 Claims. (Cl. 260-243) This invention is concerned with therapeutically active derivatives of lH-2,l,3-benzothiadiazin-4(3H)-one 2- oxide and with novel aminobenzamides which occur as intermediates in the preparation of such derivatives. These compounds exert a psycholeptic action on the central nervous system.
The compounds of this invention may be characterized as having a 11-1 2,1,3 benzothiadiazin 4(3I-I) one 2-oxide nucleus to which is attached: in the 1-position, a lower alkyl group; in the 3-position, a lower alkyl, an halo(1ower)alkyl, an alkoxyalkyl, a phenyl(lower)alkyl, an halophenyl(lower)alkyl, or a cycloalkyl group and optionally, in the 6-position, a hydrogen atom, a halogen atom, a nitro group, or a lower alkylsulfamoyl group.
Preferred compounds in accordance with the present invention are represented by the following general formula:
wherein R'is lower alkyl preferably having from 1 to 4 carbon atoms in the alkyl chain, halo(lower)alky1 preferably having from 1 to 4 carbon atoms, lower alkoxy (lower) alkyl preferably having from 1 to 4 carbon atoms, phenyl(lower)alkyl preferably having from 1 to 4 carbon atoms in the alkyl chain, halo phenyl(lower)alkyl preferably having from 1 to 4 carbon atoms in the alkyl chain, or a cycloalkyl group preferably having up to 6 carbon atoms; X is hydrogen, chlorine, nitro, or a lower alkylsulfamoyl group preferably having up to 2 carbon atoms in the alkyl chain; R is lower alkyl preferably having from 1 to 4 carbon atoms. As employed herein, the term alkyl refers both to the normal and the branched chain radicals.
The intermediates which occur in the synthesis of the present compounds may be characterized as having a 2-(lower)alkyl-aminobenzamide nucleus having attached thereto, in the -position, a hydrogen atom, a halogen atom, a nitro group or a lower alkylsulfamoyl group; on the nitrogen atom of the amido group, a lower alkyl group, a halo(lower)alkyl, an alkoxyalkyl, a hydroxyalkyl, a phenyl(lower)alkyl, an halo phenyl(lower) alkyl group or a cycloalkyl group. These intermediates are represented by the structural formula:
II E
wherein X and R are as defined under Formula I, above,
and R encompasses the same substituents as R above,
and additionally represents an hydroxy(lower)alkyl radical preferably having up to 4 carbon atoms. In the course of the reaction leading to the final products this substituent is chlorinated by the reagent used therein.
The compounds of this invention are prepared by amidating in an equeous or alcoholic solvent'or in a mix- 3,217,001 Patented Nov. 9, 1965 ture of such solvents a N-(lower) alkyl isatoic anhydride (III) of the formula:
where X and R are as above, with a primary amine of the formula (IV) R NH where R, is as above defined, to form the intermediate benzamide (II). The latter compound is then refluxed with excess thionyl chloride for one to three hours. Removal of the excess thionyl chloride affords the desired product (I). This sequence of reactions may be represented schematically as follows:
0. t O H X- X- -iiNR1 5 O +R1NHz NH N \N SeO (I) The following specific examples serve to illustrate but are not intended to limit the present invention.
Example 1 To a solution of 3.1 g. of ethanolamine in 40 ml. of ethanol was added 10.5 g. of 6-ch'loro-N-methylisatoic 'anhydride. The reaction mixture was warmed for a few minutes on the steam bath. After the evolution of carbon dioxide was complete, the solvent was removed on a rotary evaporator. The oily residue crystallized to a solid mass on cooling and amounted to 6.7 g., M.P. 1-l6122. Recrystallization from benzene afforded 5-chloro-N-(2-hydroxyethyl)-2-methylaminobenzamide, M.P. 125 .5129.
Analysis.Calculated: C=52.53, H=5.73, N=12.25, Cl=15.51. Found: C=52.60, H=5.51, N=12.53, Cl: 15.51.
When tested pharmacologically, this compound exhibited analgesic, diuretic, anticonvulsant, and anti-tremorine activities.
Example 2 To 50 ml. of 33% aqueous ethylamine solution was added 5.2 g. of 6-chloro-N-methylisatoic anhydride. After warming for a few minutes on the steam bath, the evolution of carbon dioxide ceased. The reaction mixture was allowed to stand an additional hour at room temperature. The crystalline material which deposited out of solution amounted to 5.2 g., M.P. 109112. Recrystallization from cyclohexane gave S-chloro-N-ethyl-Z- methylaminobenz amide, M.P. 96.5.'
Analysis.Ca1culated: C=56.47, H=6.16, N=13.17, Cl=16.67. Found: C=56.58, H=6.06, N==l3.30, CI: 16.4.
When tested pharmacologically, this compound exhibited analgesic, anti-metrazol and anti-tremorine activities.
Example 3 To a solution of 7.1 g. of o-chlorobenzylamine in 50 ml. of ethanol was added 11.5 g. of 6-chloro-N-methylisatoic anhydride. The reaction mixture was heated on the steam bath until the evolution of carbon dioxide ceased, and complete dissolution of solids was attained. The reaction mixture was filtered. A white crystalline product was deposited out of solution which amounted to 9.9 g., M.P. 133-6. Recrystallization of the product from ethanol afforded 5-chloro-N-(o-chlorobenzyl)-2- methylaminobenzamide, M.P. 137.5-139.
Analysis-Calculated: =58.27, H:4.56, N:9.06, 01:22.93. Found: 0:58.54, H:4.41, N:8.77, 01: 22.5.
Example 4 'To a solution of 4.5 g. of 2-ethoxyethylamine in 50 ml. of ethanol was added 11.5 g. of 6-chloro-N-methylisatoic anhydride. After the evolution of carbon dioxide had abated, the reaction mixture was heated for an additional 5 minutes on the steam bath. The solvent was removed on a rotary evaporator. The residual oil crystallized on standing in the cold room. The product, which amounted to 13.0 g., M.P. 50-63", was recrystallized from cyclohexane affording 5-chloro-N-(2-ethoxyethyl)-2-methylaminobenzamide, M.P. 73.4.
I Analysis.0alculated: 0:56.14, H:6.67, N=10.91, 01:13.81. Found: 0:55.90, H=6.47, N:l1.05, 01: 13.86.
When tested pharmacologically, this compound exhibited analgesic, anticonvulsant and central nervous system depressant activities.
Example 5 T o a solution of 9.68 g. of phenethylamine in 50 ml. of ethanol was added 15.9 g. of 6-chloro-N-methylisatoic anhydride. A brisk evolution of carbon dioxide occurred after warming for a few minutes on the steam bath. When gas evolution had abated, the reaction mixture was heated to the boiling point until dissolution of the solids had occurred. The reaction mixture was filtered. A white crystalline product was deposited out of solution. This on removal amounted to 16.0 g., M.P. 126-131. The product was recrystallized from ethanol afiording 5- chloro 2 methylamino N phenethylbenzamide, M.P. 132-4".
Analysis.-Calculated: 0:66.54, H:5.93, N:9.70, 01:12.27. Found: 0:66.41, H:5.90, N:9.73, 01: 12.3.
Example 6 .To a solution of 6.4 g. of cyclopentylamine in 40 m1. of ethanol was added 15.9 g. of 6-chloro-N-methylisatoic anhydride. The reaction mixture was heated for a few minutes on the steam bath until the evolution of carbon dioxide was completed. The solvent was removed on the rotary evaporator. The solid residue amounted to 16.5 g., M.P. 59-85. Recrystallization of the product from cyclohexane afforded 5-chloro-N-cyclopentyl-2-methylaminobenzamide, M.P. 153-5.
Analysis-Calculated: 0:61.77, H:6.78, N=l1.08, 01:14.03. Found: 0:61.50, H:6.74, N=11.36, Cl: 13.9.
Example 7 To a solution of 3.1 g. of 2-hydroxyethylamine in 40 ml. of ethanol was added 11.1 g. of 6-nitro-N-methylisatoic anhydride. After the evolution of carbon dioxide was complete, the reaction mixture was heated on the steam bath for a few minutes. The yellow crystalline product which separated was removed by filtration. The product weighed 9 g., M.P. 160-5". Recrystallization from ethyl acetate afforded N-(Z-hydroxyethyl)-2-methylamino-S-nitrobenzamide, M.P. 173-4.
Analysis.-Calculated: 0:50.20, H:5.45, N:15.57 Found: 0: 49.94, H:5.42, N:15.70.
When tested pharmacologically, this compound exhibited analgesic, anticonvulsant and central nervous system depressant activities.
Example 8 To a solution of 8.6 g. of o-chlorobenzylamine in 40.
ml. of ethanol was added 10.6 g. of N-methylisatoic anhydride. The reaction mixture was heated on the steam bath for 15 minutes and then filtered. A white crystalline product was deposited out of solution and amounted to 12.7 g., M.P. 132-3. The product was recrystallized from ethanol afiording N-(o-chlorobenzyl)-2-methylaminobenzamide, M.P. 133-134".
Analysis.0alculate: 0:65.58, H:5.50, N:10.20, 01:12.91. Found: 0:65.26, H:5.43, N:10.20, 01:13.0.
When tested pharmacologically, this compound exhibited analgesic activity.
Example 9 Example 10 A solution of 3.4 g. of 5-chloro-N-ethyl-2-methy1aminobenzamide in 40 ml. of thionyl chloride was boiled under reflux for 1 hour. The excess thionyl chloride was removed in vacuo on a rotary evaporator. The oil residue crystallized on cooling to give 3.9 g. of product, M.P. 89-92. The product was recrystallized from ethanol giving 6-chloro-3-ethyl-l-methyl-lH-Z,1,3-benzothiadiazin- 4(3H)-one 2-oxide, M.P. -96.5.
Analysis.-0alculated: 0:46.42, H:4.28, N:10.83, 01:1370, 5:12.39. Found: 0:46.62, H:4.43, N:10.73, 01:13.7, S: 12.3.
When tested pharmacologically, this compound exhibited analgesic, anti-convulsant, anti-tremorine and central nervous system depressant activities.
Example 11 A solution of 9.3 g. of S-chloro-N-(o-chlorobenzyl)-2- methylaminobenzamide in 45 ml. of thionyl chloride was heated under reflux for 2 hours. The excess thionyl chloride was removed in vacuo on a rotary evaporator. The solid residue amounted to 10.8 g., M.P. 142-5 Recrystallization from ethanol aiforded 6-chloro-3-(o-chlorobenzyl) l-methyl-1H-2,l,3-benzothiadiazin-4(3H)-one 2-oxide,,M.P. 148-1495".
Analysis.-0alculated: 0:50.71, H:3.40, N:7.89, 01:19.96, 5:9.03. Found: 0:50.85, H:3.49, N=7.89, 01:19.7, 8:8.8.
Example 12 A solution of 5.3 g. of S-chloro-N-(2-ethoxyethyl)-2- methylaminobenzamide in 25 ml. of thionyl chloride was boiled under reflux for 1 hour. The excess thionyl chloride was removed in vacuo on a rotary evaporator. The oily residue crystallized to a gummy solid weighing 6.2 g. Recrystallization of the product from cyclohexane afforded 6 chloro-3-(Z-ethoxyethyl)-1-methy1-1H-2,1,3-benzothiadiazin-(4(3H)-one-2-oxide, M.P. 73-4".
Analysis.Calculated: 0:47.60, H:4.99, N:9.25, 01:11.71, S:10.59. Found: 0:47.38, H:4.98, N:9.32, 01:11.71, S:10.2.
Example 13 A solution of 11 g. of 5-chloro-2-methylamino-N- phenethylbenzarnide in 40 ml. of thionyl chloride was boiled under reflux for 1 hour. The excess thionyl chloride was removed in vacuo on the rotary evaporator. The solid residue amounted to 13.0 g., M.P. 118123. The compound was recrystallized from ethanol alfording 6- chloro l methyl-3-phenethyl-1H-2,1,3-benzothiadiazin- 4(3H)-one 2-oxide, M.P. 127128.5.
Analysis.Calculated: C:57.57, H:4.23, N:8.39,
Cl=10.62, 8:9.60. Found: :57.50, H:4.45, N:8.21, Cl:10.82, S:9.53.
Example 14 A solution of 5.2 g. of 5-chloro-N-cyclopentyl-2-methylaminobenzamide in 30 ml. of thionyl chloride was boiled under reflux for 2 hours. The excess thionyl chloride was removed in vacuo on a rotary evaporator. The oily residue crystallized on cooling to a solid, weighing 5 g. Recrystallization from cyclohexane afforded 6 chloro-3-cyclopentyl-1-methyl-1H2,1,3 benzothiadiazin- 4(3H)-one-2-oxide, M.P. 1279.
Analysis.Calculated: (3:52.25, H:5.05, N:9.38, Cl:1l.87, 8:10.73. Found: 0:52.49, H:5.12, N:9.32, Cl:11.84, S:10.8.
Example A solution of 4 g. of N-(Z-hydroxyethyl)-2-methylamino5-nit-robenzamide in ml. of thionyl chloride was boiled under reflux for 2 hours. The excess thionyl chloride was removed in vacuo on a rotary evaporator. The solid residue amounted to 3.4 g., M.P. 145-50". Recrystallization from aqueous 2-ethoxyethanol afforded 3- (Lchloroethyl)-1-methyl-6-nitro-1H 2,1,3 benzothiadiazin-4(3H)-one-2-oxide, M.P. 16l-162.
Analysis.Calculated: C=39.54, H:3.32, N=13.84, Cl:11.67, 8:10.56. Found: C:39.69, H:3.25, N:13.68, Cl:11.85, S=10.1.
When tested pharmacologically, this compound exhibited analgesic activity.
Example 16 The reaction between 8.7 g. of N-(o-chlorobenzyl)-2- methylaminobenzamide and 40 ml. of thionyl chloride as in Example 9 affords 3-(o-chlorobenzyl)-1-methyl-1H 2,1,3-benzothiadiazin-4(3H)one-2-oxide.
Example 17 The reaction between 50 ml. of 33% aqueous ethylamine solution and 5.65 g. of 6-chloro-N-ethylisatoic anhydride aflords 5-chloro-N-ethyl-2-ethylaminobenzamide.
Example 18 The reaction between 4.5 g. of S-chloro-N-ethyl-Z-ethylaminobenzamide with 40 ml. of thionyl chloride as in Example 9 affords 6-chloro-1,3-diethyl-1H-2,1,3-benzothiadiazin-4(3H)-one-2-oxide.
Example 19 A solution of 26.5 g. of N-methylisatoic anhydride in 70 ml. of chlorosulfonic acid was heated for 1 hour on the steam bath, cooled and poured onto ice. The solid which separated was removed by filtration and was washed several times with water. The solid was added to 75 ml. of 33% aqueous ethylamine and then heated on the steam bath for 15 minutes. After cooling the reaction mixture, there was obtained 29.5 g. of product, M.P. -105 Recrystallization from aqueous ethanol afforded N-ethyl- S-ethylsulfamoyl 2 methylaminobeuzamide, M.P. 118- 120.
Analysis.Calculated: C=50.51, H:6.71, N=14.72, S:11.24. Found: 0:50.31, H:6.47, N: 14.76, S:1 1.4.
The compounds of this invention can be administered with pharmaceutically acceptable inert carriers in a wide. variety of oral or parenteral unit dosage forms containing from 5 to 500 mg. of active ingredients for the symptomatic adjustment of the dosage to the individual patient, or in admixture with other active compounds.
The present invention also includes the process of bringing the compounds thereof into a form suitable for therapeutic administration by associating them with liquid or solid, pharmaceutically acceptable carriers.
What is claimed is: 1. A compound having a 1H-2,1,3-benzothiadiazin-4- (3H)-one 2-oxide nucleus, said nucleus having attached thereto:
in the 1-position: a lower alkyl group; in the 3-position: a member of the group consisting of lower alkyl, halo (lower)a1kyl, (lower)a1koxy (lower) alkyl, phenyl and halophenyl(lower)alkyl and cycloalkyl having up to six carbon atoms in the ring;
in the 6-position: a member selected from the group consisting of hydrogen, halogen, nitro, and (lower)- alkylsulfamoyl.
2. 6 chloro 3 (2 chloroethyl) 1 methyl 1H- 2,1,3-benzothiadiazine-4(3H)-one 2-oxide.
3. 6 chloro 3 ethyl 1 methyl 1H 2,1,3 benzothiadiazin-4(3H)-one 2-oxide.
4. 6 chloro 3 (o chlorobenzyl) 1 methyl 1H- 2, 1 ,3-benzothiadiazine-4 (3H) -one 2-oxide.
5. 6 chloro 3 (2 ethoxyethyl) 1 methyl 1H- 2,1,3-benzothiadiazin-4(3H)-one 2-oxide.
6. 6 chloro 1 methyl 3 phenethyl 1H 2,1,3- benzothiadiazin-4(3H)-one 2-oxide.
7. 6 chloro 3 cyclopentyl 1 methyl 1H 2,1,3- benzothiadiazin-4(3H)-one Z-oxide.
8. 3 (2 chloroethyl) 1 methyl 6 nitro 1H- 2,l,3-benzothiadiazin-4(3H)-0ne 2-oxide.
9. 3 ethyl 6 ethylsulfamoyl 1 -methyl 1H 2,1,3- benzothiadiazin-4(3H)-one 2-oxide.
10. The process which comprises reacting in an alcoholic solvent a N-(lower)alkylisatoic anhydride of the formula:
wherein X is selected from the group consisting of hydrogen, halogen lower alkylsulfamoyl and nitro and R is a lower alkyl group; with a primary amine of the formula:
R NH wherein R is selected from the group consisting from (lower)alkyl, halo(lower) alkyl, hydroxyalkyl alkoxyalkyl, (lower)alkoxy, aralkyl, halo aralkyl and cycloalkyl to form a Z-aIkyIamino-beuzamide of the formula:
wherein X, R and R are as above stated; and further reacting said latter compound with thionyl chloride to form a compound of the formula:
References Cited by the Examiner UNITED STATES PATENTS 2,624,729 1/ 5 3 Melamed, et a1 260243 5 2,671,805 3/54 Krimmel 260558 0 3,006,916 10/ 61 Winthrop et a1. 260243 A 3,041,336 6/62 Teufel et al 260243 X 3,063,995 11/62 Bernstein et al 260243 3,066,167 11/62 Horrorn 260558 10 OTHER REFERENCES German printed application, S.N. 1,091,120, October Cohen et a1.: I.A.C.S. 84, 1995-2002.
from the group consisting of (lower) alkyl, halo(lower)- 15 WALTER A. MODANCE, Primary Examiner.
wherein X and R are as above stated and R is selected alkyl, alkoxyalkyl, aralkyl, halo aralkyl and cycloalkyl.
NICHOLAS S. RIZZO, Examiner.

Claims (1)

1. A COMPOUND HAVING A 1H-2,1,3-BENZOTHIADIAZIN-4(3H)-ONE 2-OXIDE NUCLEUS HAVING ATTACHED THERETO: IN THE 1-POSITION: A LOWER ALKYL GROUP; IN THE 3-POSITION: A MEMBER OF THE GROUP CONSISTING OF LOWER ALKYL, HALO (LOWER)ALKYL, (LOWER)ALKOXY (LOWER)ALKYL, PHENYL- AND HALOPHENYL(LOWER)ALKYL AND CYCLOAKYL HAING UP TO SIX CARBON ATOMS IN THE RING; IN THE 6-POSITION: A MEMBER SELECTED FROM THE GROUP CONSISTING OF HYDROGEN, HALOGEN, NITRO, AND (LOWER)ALKYLSULFAMOYL.
US303155A 1963-08-19 1963-08-19 Derivatives of 1h-2, 1, 3-benzothiadiazin-4(3h)-one 2-oxide and intermediates therefor Expired - Lifetime US3217001A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US303155A US3217001A (en) 1963-08-19 1963-08-19 Derivatives of 1h-2, 1, 3-benzothiadiazin-4(3h)-one 2-oxide and intermediates therefor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US303155A US3217001A (en) 1963-08-19 1963-08-19 Derivatives of 1h-2, 1, 3-benzothiadiazin-4(3h)-one 2-oxide and intermediates therefor

Publications (1)

Publication Number Publication Date
US3217001A true US3217001A (en) 1965-11-09

Family

ID=23170762

Family Applications (1)

Application Number Title Priority Date Filing Date
US303155A Expired - Lifetime US3217001A (en) 1963-08-19 1963-08-19 Derivatives of 1h-2, 1, 3-benzothiadiazin-4(3h)-one 2-oxide and intermediates therefor

Country Status (1)

Country Link
US (1) US3217001A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409668A (en) * 1964-11-07 1968-11-05 Palazzo Giuseppe Substituted anthranilamides and process for the preparation thereof
US3452019A (en) * 1967-11-16 1969-06-24 Wallace & Tiernan Inc 1-phenylalkyl-tetrahydro-halo-sulfamyl-quinazolinone
NL7412188A (en) * 1973-09-17 1975-03-19 Dow Chemical Co PROCESS FOR THE PREPARATION OF HERBICIDE PREPARATIONS BASED ON SUBSTITUTED BENZOTHIADIAZINE DIOXYDES.
FR2373536A1 (en) * 1976-12-11 1978-07-07 Basf Ag DERI
US4113939A (en) * 1974-12-10 1978-09-12 Basf Aktiengesellschaft N',N'-disubstituted 2,1,3-benzothiadiazin-(4)-one-2,2-dioxides
FR2383177A1 (en) * 1977-03-10 1978-10-06 Basf Ag PROCESS FOR PREPARING 2,1,3-THIADIAZINE-4-ONE-2,2-DIOXIDE DERIVATIVES
US4158559A (en) * 1976-12-11 1979-06-19 Basf Aktiengesellschaft Substituted 2,1,3-benzothiadiazine compounds
US4447257A (en) * 1981-11-16 1984-05-08 The Dow Chemical Company Inhibiting the antagonism between pyridyloxy-phenoxy alkanoate herbicides and benzothiadiazinone herbicides in post-emergent applications
US4942143A (en) * 1987-04-08 1990-07-17 Hoechst Japan Limited Imidazothiadiazine derivatives, and their use as medicaments

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624729A (en) * 1950-12-01 1953-01-06 Rohm & Haas Heterocyclic compounds containing sulfur and nitrogen in the ring
US2671805A (en) * 1952-07-02 1954-03-09 Searle & Co Basically substituted o-arylamino-benzamides
US3006916A (en) * 1961-10-31 W-dialkylaminoalkyl
US3041336A (en) * 1958-10-01 1962-06-26 Norwich Pharma Co 3-oxo-1.2.6-thiadiazine-1.1-dioxides
US3063995A (en) * 1958-04-25 1962-11-13 Olin Mathieson Derivatives of pyridothiadiazine-1, 1-dioxides
US3066167A (en) * 1961-02-16 1962-11-27 Abbott Lab 4-amino-3, 5-dichloro-benzamides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3006916A (en) * 1961-10-31 W-dialkylaminoalkyl
US2624729A (en) * 1950-12-01 1953-01-06 Rohm & Haas Heterocyclic compounds containing sulfur and nitrogen in the ring
US2671805A (en) * 1952-07-02 1954-03-09 Searle & Co Basically substituted o-arylamino-benzamides
US3063995A (en) * 1958-04-25 1962-11-13 Olin Mathieson Derivatives of pyridothiadiazine-1, 1-dioxides
US3041336A (en) * 1958-10-01 1962-06-26 Norwich Pharma Co 3-oxo-1.2.6-thiadiazine-1.1-dioxides
US3066167A (en) * 1961-02-16 1962-11-27 Abbott Lab 4-amino-3, 5-dichloro-benzamides

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409668A (en) * 1964-11-07 1968-11-05 Palazzo Giuseppe Substituted anthranilamides and process for the preparation thereof
US3452019A (en) * 1967-11-16 1969-06-24 Wallace & Tiernan Inc 1-phenylalkyl-tetrahydro-halo-sulfamyl-quinazolinone
NL7412188A (en) * 1973-09-17 1975-03-19 Dow Chemical Co PROCESS FOR THE PREPARATION OF HERBICIDE PREPARATIONS BASED ON SUBSTITUTED BENZOTHIADIAZINE DIOXYDES.
DE2444383A1 (en) * 1973-09-17 1975-03-20 Dow Chemical Co BENZOTHIADIAZINE COMPOUNDS AND HERBICIDES CONTAINING THEM
US4113939A (en) * 1974-12-10 1978-09-12 Basf Aktiengesellschaft N',N'-disubstituted 2,1,3-benzothiadiazin-(4)-one-2,2-dioxides
FR2373536A1 (en) * 1976-12-11 1978-07-07 Basf Ag DERI
US4158559A (en) * 1976-12-11 1979-06-19 Basf Aktiengesellschaft Substituted 2,1,3-benzothiadiazine compounds
US4298731A (en) * 1976-12-11 1981-11-03 Basf Aktiengesellschaft Benzothiadiazine compounds
FR2383177A1 (en) * 1977-03-10 1978-10-06 Basf Ag PROCESS FOR PREPARING 2,1,3-THIADIAZINE-4-ONE-2,2-DIOXIDE DERIVATIVES
US4447257A (en) * 1981-11-16 1984-05-08 The Dow Chemical Company Inhibiting the antagonism between pyridyloxy-phenoxy alkanoate herbicides and benzothiadiazinone herbicides in post-emergent applications
US4942143A (en) * 1987-04-08 1990-07-17 Hoechst Japan Limited Imidazothiadiazine derivatives, and their use as medicaments

Similar Documents

Publication Publication Date Title
US2910488A (en) Aniline derivatives
US3217001A (en) Derivatives of 1h-2, 1, 3-benzothiadiazin-4(3h)-one 2-oxide and intermediates therefor
US3374264A (en) N-haloacetyl-anthranilic acids and esters
CS251795B2 (en) Method of 5h-2,3-benzodiazepine's derivatives preparation
CN105272904A (en) N-pheny-lamide compounds and applications thereof
US2852510A (en) Heterocyclic compounds and process for producing same
US3725404A (en) 2-amino-4,4-di-substituted-4h-3,1-benzoxazines
US3515723A (en) 2 - (5 - amino - 1h - 1,2,4 - triazol - 3 - yl)- 3-aminopyrazines and processes for their preparation
US3538086A (en) 4-oxo-4h-pyrimido 2,1-b benzothiazoles
US3200123A (en) Imidazoquinolines
US3668207A (en) 2-amino-4-aryl-quinolines
US3133056A (en) N-phenylpiperazine derivatives of tetrahydrobenzodiazepines
US3726875A (en) 1,3(2h,4h)-dioxoisoquinoline-4-carboxylate esters and process therefor
US2952680A (en) Derivatives of x-quevazolone
US3674787A (en) 2-(alpha-morpholinobenzyl)-anilides
US3383382A (en) N-amino-iminodibenzyl
US3351659A (en) Aminobenzamides
US3403153A (en) 1-aryl-4-imino-1, 2-dihydroquinazolines
US3019245A (en) Halo-disulfamylanilines
US3420818A (en) Tetrahydroisoquinolines
US3277086A (en) 1, 2, 4-benzothiadiazine 1, 1-dioxides having a heterocyclic ring fused to the "b" face thereof
US3361816A (en) Novel therapeutic compounds and processes for their manufacture
US3951985A (en) Lactams and process for their manufacture
US3471473A (en) 6,11-diamino-morphanthridines
US3574194A (en) 1-alpha-ethyl - alpha - methyl-succinimido) -4-sulphonamidobenzene and related compounds